GoKawiilBase-editing therapy durably silences ANGPTL3 gene to cut lipids in primates
Researchers developed a CRISPR adenine base editor delivered via a GalNAc-lipid nanoparticle that makes a single DNA edit in liver cells to inactivate ANGPTL3, a gene linked to high LDL cholesterol and triglycerides. In nonhuman primates, a single infusion cut circulating ANGPTL3 protein by over 90%, an effect sustained for three years, while animal models showed LDL-C reductions of 40-50% and triglyceride reductions of 50-70%, with no detectable off-target edits found in vitro.
GoKawiil's interpretation of the reporting above, not reported fact.
These preclinical results suggest a one-time gene-editing treatment could replace daily pills or repeated injections for lipid disorders, potentially addressing the common problem of patients failing to hit cholesterol targets under current chronic therapies. The data have already supported launch of a first-in-human trial in patients with refractory hyperlipidemia, meaning real-world efficacy and safety in humans remain to be confirmed.
- A single-dose CRISPR base editor achieved durable ANGPTL3 inactivation lasting up to three years in primates.
- Lipid reductions reached 40-50% for LDL-C and 50-70% for triglycerides in animal hyperlipidemia models.
- Findings underpin an ongoing first-in-human clinical trial for refractory hyperlipidemia syndromes.
Source: nature.com — Mizoguchi, 2026-11-06
Published there as: “In Vivo CRISPR Base Editing of <i>ANGPTL3</i> for Durable Lipid Lowering”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.